Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Change in Account Payables (2023 - 2025)

Historic Change in Account Payables for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $500000.0.

  • Compass Therapeutics' Change in Account Payables rose 31551.72% to $500000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 25861.81%. This contributed to the annual value of -$1.8 million for FY2024, which is 36002.82% down from last year.
  • Latest data reveals that Compass Therapeutics reported Change in Account Payables of $500000.0 as of Q3 2025, which was up 31551.72% from $1.0 million recorded in Q2 2025.
  • Over the past 5 years, Compass Therapeutics' Change in Account Payables peaked at $1.8 million during Q4 2023, and registered a low of -$3.2 million during Q1 2024.
  • In the last 3 years, Compass Therapeutics' Change in Account Payables had a median value of $338000.0 in 2024 and averaged -$26090.9.
  • Its Change in Account Payables has fluctuated over the past 5 years, first tumbled by 11466.5% in 2024, then soared by 31551.72% in 2025.
  • Quarter analysis of 3 years shows Compass Therapeutics' Change in Account Payables stood at $1.8 million in 2023, then dropped by 27.75% to $1.3 million in 2024, then crashed by 61.21% to $500000.0 in 2025.
  • Its last three reported values are $500000.0 in Q3 2025, $1.0 million for Q2 2025, and -$672000.0 during Q1 2025.